High Caffeine Intake Wards Off Death in CKD Patients
Caffeine consumption is associated with a lower risk of mortality among individuals with chronic kidney disease (CKD), according to a recent study.
Findings were presented at the American Society of Nephrology (ASN) Kidney Week 2017, which took place from October 31 to November 5, 2017 in New Orleans, Louisiana.
_________________________________________________________________________
RELATED CONTENT
Good-Cholesterol Levels Determine Mortality Risk in CKD Patients
New Risk Score For Heart Disease in CKD Patients
_________________________________________________________________________
Previous evidence has demonstrated an inverse relationship between coffee consumption and mortality in the general population. However, less is currently known about the association between caffeine consumption and mortality specifically in patients with CKD.
Using data from the 1999-2010 National Health and Nutrition Examination Survey (NHANES), the researchers evaluated a nationwide cohort of 2328 patients with CKD (defined as having an estimated glomerular filtration rate [eGFR] of less than 60 mL/min/1.73m2, based on the CKD-EPI equation).
Patients were categorized based on their caffeine consumption: less than 29.5 mg of caffeine/day (1st quartile), 30.5 to 101.0 mg/day (2nd quartile), 101.5 to 206.0 mg/day (3rd quartile), and 206.5 to 1378.5 mg/day (4th quartile).
At baseline, caffeine consumption was examined via 24-hour dietary recalls. Hazard ratios (HRs) for all-cause mortality were estimated based on caffeine consumption with Cox proportional hazard models. The researchers also assessed how CKD stage impacted the effects of caffeine consumption on mortality.
Findings demonstrated a dose-dependent inverse association between caffeine and all-cause mortality in patients with CKD. The adjusted HRs for mortality were 0.88 (2nd quartile), 0.78 (3rd quartile), and 0.76 (4th quartile), compared with the 1st quartile.
The researchers did not observe any significant interactions between the quartiles of caffeine consumption and CKD stages in relation to all-cause mortality.
“Our study showed a dose-dependent protective effect of caffeine consumption on mortality among patients with CKD,” the researchers concluded.
—Christina Vogt
Reference:
Bigotte Vieira M, Magriço R, Viegas dias C, Leitão L, Neves JS. Caffeine consumption and mortality in CKD. Paper presented at: ASN Kidney Week 2017; October 31-November 5, 2017; New Orleans, LA. https://www.asn-online.org/education/kidneyweek/2017/program-abstract.aspx?controlId=2784081.